Shots:

• Entrada will receive $224M up front, $26M in equity investment, and ~$485M upon achievement of research, development, regulatory & commercial milestones along with royalties on net sales of products
• Entrada will continue to advance research activities related to ENTR-701 and additional DM1-related research activities. Vertex will lead the global development, manufacturing & commercialization of ENTR-701 along with an additional program from Entrada’s DM1 research efforts
• The agreement includes a 4yr. research collaboration along with ENTR-701 (currently in late-stage preclinical development) for DM1. The preclinical studies of ENTR-701 suggested the correction of disease-relevant biomarkers in multiple muscle groups

Ref: Businesswire | Image: Vertex